Dr. Andreas Amrein

Leading global Rare and Specialty Care portfolio with sales of $1 billion and growing 30% with focus on China, US and India. • Updated portfolio strategy with geographic expansion • Led global relaunch of Flexbumin brand • Drove new growth strategy for China based on marketing, sales force expansion, new channels and market access

Led rare disease HAE portfolio with $1.4 billion sales through line extensions, new indications and launches into JAPAC, EAMEA, LATAM • Updated portfolio strategy with geographic expansion and repositioning • Established cross-function global leadership teams with new talents and led through merger integration and integration • Launched new indications and led LCM activities to defend against generic erosion • Ensured patient treatment availability within constrained supply situations

Drove global expansion for private equity-owned contract research organization offering Phase I bio-availability and bio-equivalence studies, Phase II-IV clinical trials, and bio-analytical services for biologics and biosimilars. Built teams covering the US, EU, Asia Pacific, Latin America, and Middle East. Established and leveraged profitable relationships with industry leaders. Negotiated high-revenue contracts

Ensured profitability of business operations throughout $200 million region spanning China, Japan, India, Australia, Taiwan, South Korea, Hong Kong and ASEAN countries. Directed team of over 500 locally and remotely. Strengthened commercial effectiveness with innovative Business Intelligence platform, streamlined functions, processes, and procedures governing sales, marketing, distribution, scientific affairs and QA/RA. Directed top talent recruitment and retention strategy

Upgraded commercial operations for organization worth over $430 million during aggressive expansion. Coordinated 150-person management team responsible for more than 1,300. Directed development and launch of commercial content, activities, and processes

Led $230 million marketing, sales and medical team overseeing sales force of 780

Restored growth of Pharma organization with 200 employees in key emerging market

Developed, launched, and directed strategic planning organization and special commercial projects serving all APAC countries. Influenced Head of Country positions and commercial teams of over 1,600. Prepared and reviewed budgets, estimates, and P&L forecasting

Directed more than 100 M&A projects worth between $150 million and $11 billion, overseeing teams of up to 70 during due diligences. Led divestment of non-core businesses, introduced corporate-wide M&A procedures and business valuation models • Led project and due diligence for acquisition of LEK, closing at $850 million • Led divestiture project of food and beverage business

Coordinated group-wide strategic planning and executive information system for global business of USD 31bn and organization of 82,000 organized in 5 Divisions (Pharma, OTC, Generics, Eye Care, Agribusiness).

Equity research, risks for derivative traders, indexed equity portfolios, company valuation instruments.

Swiss engineering company specialized in portable digital assistants for the visually impaired

M&A, Finance, Marketing, Strategy